Richard Turnage
Concepts (485)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Intestines | 18 | 1998 | 176 | 1.700 |
Why?
| Reperfusion Injury | 17 | 2005 | 87 | 1.610 |
Why?
| General Surgery | 4 | 2014 | 105 | 0.910 |
Why?
| Capillary Permeability | 8 | 2003 | 35 | 0.780 |
Why?
| Tumor Necrosis Factor-alpha | 6 | 2003 | 388 | 0.760 |
Why?
| Lung | 13 | 2003 | 486 | 0.680 |
Why?
| Neutrophils | 6 | 2002 | 145 | 0.560 |
Why?
| Burns | 4 | 2003 | 162 | 0.560 |
Why?
| Rats | 32 | 2005 | 3305 | 0.550 |
Why?
| Rats, Sprague-Dawley | 27 | 2005 | 1597 | 0.550 |
Why?
| Ischemia | 7 | 1998 | 153 | 0.540 |
Why?
| Keratinocytes | 3 | 2001 | 90 | 0.510 |
Why?
| Thromboxane A2 | 4 | 2002 | 16 | 0.490 |
Why?
| Pulmonary Circulation | 6 | 2003 | 33 | 0.490 |
Why?
| Endothelium, Vascular | 7 | 2003 | 252 | 0.480 |
Why?
| Private Practice | 1 | 2014 | 10 | 0.480 |
Why?
| Financial Management | 1 | 2014 | 10 | 0.480 |
Why?
| Internship and Residency | 3 | 2014 | 443 | 0.470 |
Why?
| Education, Medical, Graduate | 3 | 2014 | 205 | 0.450 |
Why?
| Dinoprostone | 7 | 2000 | 53 | 0.440 |
Why?
| Microcirculation | 8 | 2006 | 70 | 0.440 |
Why?
| Nitric Oxide | 4 | 2006 | 253 | 0.430 |
Why?
| Pulmonary Edema | 4 | 1998 | 18 | 0.390 |
Why?
| Oxidants | 3 | 2006 | 53 | 0.380 |
Why?
| Epoprostenol | 8 | 2000 | 20 | 0.380 |
Why?
| Animals | 40 | 2006 | 13187 | 0.370 |
Why?
| Splanchnic Circulation | 5 | 1998 | 40 | 0.370 |
Why?
| Protein-Tyrosine Kinases | 2 | 2001 | 95 | 0.360 |
Why?
| Liability, Legal | 1 | 2009 | 12 | 0.330 |
Why?
| Malpractice | 1 | 2009 | 15 | 0.330 |
Why?
| Insurance Claim Review | 1 | 2009 | 36 | 0.330 |
Why?
| Medical Errors | 1 | 2009 | 24 | 0.330 |
Why?
| Nitric Oxide Synthase | 5 | 2006 | 75 | 0.320 |
Why?
| Cell Membrane Permeability | 2 | 2006 | 28 | 0.310 |
Why?
| Reperfusion | 3 | 1996 | 14 | 0.300 |
Why?
| Colorectal Neoplasms | 2 | 2001 | 236 | 0.290 |
Why?
| Endothelial Cells | 2 | 2006 | 269 | 0.280 |
Why?
| Attitude of Health Personnel | 1 | 2009 | 347 | 0.260 |
Why?
| Mitogen-Activated Protein Kinases | 2 | 2003 | 155 | 0.250 |
Why?
| Cadherins | 2 | 2002 | 68 | 0.250 |
Why?
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 2 | 2002 | 4 | 0.230 |
Why?
| Male | 39 | 2011 | 25241 | 0.230 |
Why?
| Liver | 5 | 2004 | 1115 | 0.230 |
Why?
| Humans | 45 | 2017 | 49974 | 0.230 |
Why?
| Duodenal Ulcer | 1 | 2003 | 12 | 0.230 |
Why?
| Gelsolin | 1 | 2003 | 2 | 0.220 |
Why?
| Insulin | 1 | 2006 | 457 | 0.220 |
Why?
| Cells, Cultured | 8 | 2006 | 1573 | 0.220 |
Why?
| Thromboxane B2 | 4 | 1998 | 8 | 0.210 |
Why?
| Colonic Neoplasms | 2 | 2003 | 161 | 0.210 |
Why?
| Respiratory Mucosa | 1 | 2002 | 10 | 0.210 |
Why?
| Pneumonia | 1 | 2003 | 118 | 0.200 |
Why?
| Antigens, CD | 3 | 2002 | 219 | 0.200 |
Why?
| Gastroesophageal Reflux | 3 | 1991 | 49 | 0.200 |
Why?
| Positron-Emission Tomography | 3 | 2010 | 295 | 0.190 |
Why?
| Lung Diseases | 1 | 2002 | 92 | 0.190 |
Why?
| Neoplasm Recurrence, Local | 4 | 2007 | 614 | 0.190 |
Why?
| Kidney | 4 | 2002 | 665 | 0.190 |
Why?
| Skin | 2 | 2003 | 409 | 0.190 |
Why?
| Hernia, Inguinal | 2 | 2000 | 18 | 0.180 |
Why?
| Neutrophil Activation | 1 | 2000 | 14 | 0.180 |
Why?
| Cytoskeleton | 1 | 2000 | 39 | 0.180 |
Why?
| Prostaglandins | 1 | 2000 | 20 | 0.180 |
Why?
| Brain Edema | 3 | 2005 | 41 | 0.180 |
Why?
| Hernia, Ventral | 1 | 2000 | 7 | 0.180 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 2000 | 60 | 0.180 |
Why?
| Actins | 1 | 2000 | 118 | 0.180 |
Why?
| Thyroid Neoplasms | 2 | 2015 | 110 | 0.170 |
Why?
| Surgical Wound Dehiscence | 1 | 2000 | 21 | 0.170 |
Why?
| Critical Pathways | 1 | 2000 | 39 | 0.170 |
Why?
| Wound Healing | 1 | 2001 | 204 | 0.170 |
Why?
| Systemic Inflammatory Response Syndrome | 1 | 1999 | 54 | 0.170 |
Why?
| Population Surveillance | 1 | 2000 | 164 | 0.170 |
Why?
| Attitude to Health | 1 | 2001 | 192 | 0.170 |
Why?
| Health Status | 1 | 2001 | 298 | 0.160 |
Why?
| Signal Transduction | 3 | 2015 | 1618 | 0.160 |
Why?
| Resuscitation | 2 | 1996 | 73 | 0.160 |
Why?
| Pulmonary Artery | 1 | 2000 | 145 | 0.160 |
Why?
| Educational Measurement | 1 | 2000 | 208 | 0.160 |
Why?
| Diabetes Mellitus, Experimental | 1 | 1999 | 129 | 0.160 |
Why?
| Lipopolysaccharides | 1 | 1999 | 192 | 0.160 |
Why?
| Lung Injury | 4 | 2003 | 25 | 0.160 |
Why?
| Macrophage Activation | 1 | 1998 | 25 | 0.160 |
Why?
| Students, Medical | 1 | 2000 | 157 | 0.150 |
Why?
| Macrophages, Alveolar | 1 | 1998 | 28 | 0.150 |
Why?
| Interleukin-2 | 1 | 2017 | 72 | 0.150 |
Why?
| Anal Gland Neoplasms | 1 | 1997 | 1 | 0.150 |
Why?
| Perfusion | 4 | 2002 | 48 | 0.140 |
Why?
| Breast Neoplasms | 4 | 2007 | 1174 | 0.140 |
Why?
| Middle Aged | 16 | 2011 | 12069 | 0.140 |
Why?
| Incidence | 5 | 2006 | 1003 | 0.140 |
Why?
| Calcineurin | 1 | 2017 | 71 | 0.140 |
Why?
| Texas | 3 | 2001 | 137 | 0.140 |
Why?
| Eukaryotic Initiation Factor-4E | 2 | 2006 | 4 | 0.140 |
Why?
| Portal Vein | 1 | 1996 | 24 | 0.130 |
Why?
| Hepatic Artery | 1 | 1996 | 21 | 0.130 |
Why?
| Amino Acid Oxidoreductases | 1 | 1995 | 6 | 0.130 |
Why?
| Promoter Regions, Genetic | 1 | 1998 | 475 | 0.130 |
Why?
| Shock, Hemorrhagic | 1 | 1995 | 11 | 0.130 |
Why?
| Phosphorylation | 5 | 2017 | 535 | 0.130 |
Why?
| Apolipoproteins A | 2 | 2005 | 2 | 0.130 |
Why?
| Carcinoma, Neuroendocrine | 1 | 2015 | 24 | 0.130 |
Why?
| Recurrence | 4 | 2003 | 652 | 0.130 |
Why?
| Hydroxyl Radical | 1 | 1994 | 6 | 0.120 |
Why?
| DNA-Activated Protein Kinase | 1 | 2015 | 26 | 0.120 |
Why?
| Proto-Oncogene Proteins c-ret | 1 | 2015 | 33 | 0.120 |
Why?
| Postoperative Complications | 5 | 2003 | 984 | 0.120 |
Why?
| Plasma Volume | 1 | 1994 | 4 | 0.120 |
Why?
| Quality of Life | 1 | 2001 | 836 | 0.120 |
Why?
| Complement Activation | 1 | 1994 | 42 | 0.120 |
Why?
| Contract Services | 1 | 2014 | 14 | 0.120 |
Why?
| Electrolytes | 1 | 1994 | 26 | 0.120 |
Why?
| Hemorrhage | 1 | 1996 | 197 | 0.120 |
Why?
| Gastric Fundus | 2 | 1991 | 8 | 0.120 |
Why?
| Imidazoles | 3 | 2006 | 119 | 0.120 |
Why?
| Endotoxins | 1 | 1994 | 34 | 0.120 |
Why?
| Physician Assistants | 1 | 2014 | 18 | 0.120 |
Why?
| Enzyme Inhibitors | 4 | 2006 | 391 | 0.120 |
Why?
| Multiple Trauma | 1 | 1994 | 32 | 0.120 |
Why?
| Risk Management | 1 | 2014 | 32 | 0.120 |
Why?
| Blood Volume | 1 | 1994 | 68 | 0.120 |
Why?
| Disease Models, Animal | 7 | 2004 | 1455 | 0.120 |
Why?
| Polyethylene Glycols | 1 | 1994 | 93 | 0.120 |
Why?
| Piperidines | 2 | 2005 | 98 | 0.110 |
Why?
| Nuclear Proteins | 1 | 2015 | 242 | 0.110 |
Why?
| Esophagus | 2 | 1991 | 84 | 0.110 |
Why?
| Renal Circulation | 4 | 1997 | 59 | 0.110 |
Why?
| Dose-Response Relationship, Drug | 4 | 2006 | 1376 | 0.110 |
Why?
| Time Factors | 6 | 2006 | 2903 | 0.110 |
Why?
| Adenocarcinoma | 1 | 1997 | 396 | 0.110 |
Why?
| Follow-Up Studies | 5 | 2005 | 2182 | 0.110 |
Why?
| Heart Arrest | 2 | 2005 | 149 | 0.100 |
Why?
| Blood Pressure | 5 | 2000 | 512 | 0.100 |
Why?
| Proteomics | 1 | 2015 | 329 | 0.100 |
Why?
| Intramolecular Oxidoreductases | 3 | 1996 | 14 | 0.100 |
Why?
| Curriculum | 1 | 2014 | 401 | 0.100 |
Why?
| Risk Factors | 7 | 2007 | 3613 | 0.090 |
Why?
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 2001 | 20 | 0.090 |
Why?
| Focal Adhesion Kinase 1 | 2 | 2001 | 15 | 0.090 |
Why?
| Enzyme Activation | 2 | 2002 | 276 | 0.090 |
Why?
| Abdominal Pain | 1 | 2011 | 81 | 0.090 |
Why?
| Aged | 8 | 2011 | 9310 | 0.090 |
Why?
| Malabsorption Syndromes | 1 | 1990 | 9 | 0.090 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 488 | 0.090 |
Why?
| Ileum | 1 | 1990 | 89 | 0.090 |
Why?
| Vascular Resistance | 2 | 2000 | 54 | 0.090 |
Why?
| Glutathione | 2 | 2005 | 295 | 0.080 |
Why?
| Pancreatic Cyst | 1 | 1988 | 11 | 0.080 |
Why?
| Chemotherapy, Adjuvant | 2 | 2001 | 119 | 0.080 |
Why?
| Random Allocation | 3 | 2004 | 281 | 0.080 |
Why?
| Recombinant Proteins | 3 | 2005 | 486 | 0.080 |
Why?
| Cysts | 1 | 1988 | 51 | 0.080 |
Why?
| Liver Diseases | 1 | 1988 | 78 | 0.070 |
Why?
| Receptors, CXCR4 | 1 | 2007 | 28 | 0.070 |
Why?
| Female | 14 | 2011 | 26472 | 0.070 |
Why?
| Nitric Oxide Donors | 2 | 2004 | 10 | 0.070 |
Why?
| Carcinoma, Hepatocellular | 1 | 2010 | 191 | 0.070 |
Why?
| Receptor, erbB-2 | 1 | 2007 | 73 | 0.070 |
Why?
| Quality of Health Care | 1 | 2009 | 186 | 0.070 |
Why?
| Eicosanoids | 2 | 1997 | 19 | 0.070 |
Why?
| Analysis of Variance | 2 | 2000 | 562 | 0.070 |
Why?
| Rabbits | 2 | 2006 | 370 | 0.070 |
Why?
| Treatment Outcome | 6 | 2011 | 5141 | 0.070 |
Why?
| Retrospective Studies | 6 | 2011 | 6108 | 0.070 |
Why?
| Carcinoma, Lobular | 1 | 2006 | 33 | 0.070 |
Why?
| Adult | 9 | 2011 | 13236 | 0.070 |
Why?
| Ornithine | 1 | 2006 | 16 | 0.070 |
Why?
| Colectomy | 2 | 2000 | 30 | 0.070 |
Why?
| Cyclic N-Oxides | 1 | 2006 | 12 | 0.070 |
Why?
| Free Radical Scavengers | 1 | 2006 | 25 | 0.070 |
Why?
| Pancreatic Neoplasms | 1 | 1988 | 208 | 0.070 |
Why?
| Cohort Studies | 2 | 2001 | 1422 | 0.070 |
Why?
| Osmolar Concentration | 1 | 2006 | 62 | 0.070 |
Why?
| Liver Neoplasms | 1 | 2010 | 326 | 0.070 |
Why?
| Electric Impedance | 1 | 2006 | 41 | 0.070 |
Why?
| Chromones | 1 | 2006 | 21 | 0.070 |
Why?
| Culture Media | 1 | 2006 | 94 | 0.070 |
Why?
| Carcinoma, Ductal, Breast | 1 | 2006 | 89 | 0.060 |
Why?
| Morpholines | 1 | 2006 | 71 | 0.060 |
Why?
| p38 Mitogen-Activated Protein Kinases | 2 | 2003 | 96 | 0.060 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2006 | 201 | 0.060 |
Why?
| Hydrogen Peroxide | 1 | 2006 | 115 | 0.060 |
Why?
| Chromatography | 1 | 2005 | 12 | 0.060 |
Why?
| Indomethacin | 3 | 2000 | 38 | 0.060 |
Why?
| Cell Separation | 1 | 2005 | 89 | 0.060 |
Why?
| Pyridines | 2 | 2003 | 130 | 0.060 |
Why?
| Aged, 80 and over | 4 | 2011 | 3129 | 0.060 |
Why?
| United States | 2 | 2009 | 4860 | 0.060 |
Why?
| Asphyxia | 1 | 2004 | 9 | 0.060 |
Why?
| Umbilical Veins | 2 | 2002 | 23 | 0.060 |
Why?
| Neoplasm Staging | 4 | 2010 | 740 | 0.060 |
Why?
| Disease-Free Survival | 2 | 2007 | 454 | 0.060 |
Why?
| Nitroso Compounds | 1 | 2004 | 4 | 0.060 |
Why?
| Excitatory Amino Acid Antagonists | 1 | 2004 | 51 | 0.060 |
Why?
| Referral and Consultation | 1 | 2006 | 285 | 0.060 |
Why?
| Colitis | 1 | 2004 | 50 | 0.060 |
Why?
| Vagotomy | 1 | 2003 | 5 | 0.060 |
Why?
| rho GTP-Binding Proteins | 1 | 2003 | 6 | 0.060 |
Why?
| Glucose | 1 | 2006 | 344 | 0.060 |
Why?
| Lymph Nodes | 1 | 2005 | 260 | 0.060 |
Why?
| Vitamin D-Binding Protein | 1 | 2003 | 4 | 0.060 |
Why?
| Mesenteric Arteries | 3 | 1998 | 45 | 0.060 |
Why?
| Prognosis | 3 | 2007 | 1942 | 0.060 |
Why?
| Hematocrit | 1 | 2003 | 44 | 0.060 |
Why?
| Epithelial Cells | 2 | 2004 | 209 | 0.060 |
Why?
| Carbon Dioxide | 1 | 2003 | 91 | 0.060 |
Why?
| Accidents, Traffic | 1 | 2003 | 88 | 0.050 |
Why?
| Myocardial Reperfusion Injury | 1 | 2003 | 48 | 0.050 |
Why?
| Aorta | 4 | 1998 | 161 | 0.050 |
Why?
| Anti-Inflammatory Agents | 1 | 2004 | 161 | 0.050 |
Why?
| Blood Proteins | 1 | 2003 | 82 | 0.050 |
Why?
| Nitric Oxide Synthase Type II | 2 | 2003 | 66 | 0.050 |
Why?
| Helicobacter pylori | 1 | 2003 | 66 | 0.050 |
Why?
| Dinoprost | 2 | 2000 | 8 | 0.050 |
Why?
| Tissue Donors | 1 | 2003 | 111 | 0.050 |
Why?
| Helicobacter Infections | 1 | 2003 | 64 | 0.050 |
Why?
| Fluorescein-5-isothiocyanate | 1 | 2002 | 7 | 0.050 |
Why?
| Infusions, Intravenous | 1 | 2003 | 206 | 0.050 |
Why?
| Receptors, Angiotensin | 1 | 2002 | 13 | 0.050 |
Why?
| Receptors, Thromboxane | 1 | 2002 | 3 | 0.050 |
Why?
| Dextrans | 1 | 2002 | 16 | 0.050 |
Why?
| Hypertension, Renovascular | 1 | 2002 | 14 | 0.050 |
Why?
| Mice | 4 | 2006 | 5739 | 0.050 |
Why?
| Brain Ischemia | 1 | 2004 | 161 | 0.050 |
Why?
| Emergencies | 1 | 2003 | 86 | 0.050 |
Why?
| Adrenal Glands | 1 | 2002 | 39 | 0.050 |
Why?
| Tyrosine | 1 | 2002 | 95 | 0.050 |
Why?
| Myocardial Ischemia | 1 | 2003 | 120 | 0.050 |
Why?
| Bronchi | 1 | 2002 | 43 | 0.050 |
Why?
| Survival Rate | 2 | 2005 | 894 | 0.050 |
Why?
| Renin-Angiotensin System | 1 | 2002 | 58 | 0.050 |
Why?
| Interleukin-1 | 1 | 2002 | 104 | 0.050 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 121 | 0.050 |
Why?
| Flavonoids | 1 | 2002 | 58 | 0.050 |
Why?
| Drug Synergism | 1 | 2002 | 150 | 0.050 |
Why?
| Rats, Wistar | 1 | 2002 | 223 | 0.050 |
Why?
| Isomerases | 3 | 1996 | 3 | 0.050 |
Why?
| Capillaries | 2 | 1998 | 50 | 0.050 |
Why?
| Intestinal Mucosa | 3 | 2004 | 225 | 0.050 |
Why?
| Inflammation Mediators | 1 | 2002 | 112 | 0.050 |
Why?
| Hospitals, Teaching | 1 | 2001 | 53 | 0.050 |
Why?
| Hospitals, Veterans | 1 | 2001 | 110 | 0.050 |
Why?
| Cell Membrane | 1 | 2002 | 248 | 0.050 |
Why?
| Gynecomastia | 1 | 2001 | 4 | 0.050 |
Why?
| Breast Neoplasms, Male | 1 | 2001 | 6 | 0.050 |
Why?
| Enzyme Induction | 1 | 2001 | 80 | 0.050 |
Why?
| Organ Culture Techniques | 1 | 2001 | 48 | 0.050 |
Why?
| Chronic Disease | 2 | 2002 | 567 | 0.050 |
Why?
| Vasodilator Agents | 2 | 2005 | 96 | 0.050 |
Why?
| Superoxides | 2 | 1998 | 46 | 0.050 |
Why?
| Oxidative Stress | 1 | 2005 | 770 | 0.050 |
Why?
| Surgical Procedures, Operative | 1 | 2001 | 63 | 0.050 |
Why?
| Alanine Transaminase | 2 | 2004 | 124 | 0.050 |
Why?
| Reference Values | 2 | 2004 | 310 | 0.050 |
Why?
| Myocardium | 1 | 2003 | 436 | 0.050 |
Why?
| Demography | 1 | 2001 | 93 | 0.050 |
Why?
| Up-Regulation | 1 | 2002 | 452 | 0.050 |
Why?
| Documentation | 1 | 2000 | 34 | 0.050 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2003 | 549 | 0.050 |
Why?
| Integrins | 1 | 2000 | 31 | 0.050 |
Why?
| Mammography | 1 | 2001 | 96 | 0.050 |
Why?
| Sex Distribution | 1 | 2000 | 134 | 0.040 |
Why?
| Age Distribution | 1 | 2000 | 168 | 0.040 |
Why?
| Cytochrome P-450 Enzyme System | 3 | 1996 | 195 | 0.040 |
Why?
| Extravascular Lung Water | 1 | 1999 | 2 | 0.040 |
Why?
| Cell Movement | 1 | 2001 | 247 | 0.040 |
Why?
| Apoptosis | 1 | 2005 | 1101 | 0.040 |
Why?
| Neutrophil Infiltration | 1 | 1999 | 26 | 0.040 |
Why?
| Pulmonary Alveoli | 1 | 1999 | 19 | 0.040 |
Why?
| Colon | 2 | 2004 | 98 | 0.040 |
Why?
| Interpersonal Relations | 1 | 2000 | 105 | 0.040 |
Why?
| Rats, Zucker | 1 | 1999 | 69 | 0.040 |
Why?
| Academic Medical Centers | 1 | 2000 | 144 | 0.040 |
Why?
| Interprofessional Relations | 1 | 2000 | 85 | 0.040 |
Why?
| Microspheres | 2 | 1996 | 25 | 0.040 |
Why?
| Faculty, Medical | 1 | 2000 | 89 | 0.040 |
Why?
| Glutathione Disulfide | 2 | 2005 | 41 | 0.040 |
Why?
| 6-Ketoprostaglandin F1 alpha | 2 | 1996 | 6 | 0.040 |
Why?
| NG-Nitroarginine Methyl Ester | 2 | 1996 | 18 | 0.040 |
Why?
| Cost-Benefit Analysis | 1 | 2000 | 274 | 0.040 |
Why?
| Body Fluids | 1 | 1998 | 20 | 0.040 |
Why?
| Regional Blood Flow | 2 | 1996 | 108 | 0.040 |
Why?
| Sensitivity and Specificity | 3 | 2010 | 861 | 0.040 |
Why?
| Collagen | 1 | 2000 | 206 | 0.040 |
Why?
| Wounds, Stab | 1 | 1998 | 6 | 0.040 |
Why?
| Specific Pathogen-Free Organisms | 1 | 1998 | 18 | 0.040 |
Why?
| Sex | 1 | 1998 | 1 | 0.040 |
Why?
| Student Dropouts | 1 | 1998 | 3 | 0.040 |
Why?
| Integrin alphaV | 1 | 1998 | 3 | 0.040 |
Why?
| Sequence Homology | 1 | 1998 | 20 | 0.040 |
Why?
| Length of Stay | 3 | 2011 | 619 | 0.040 |
Why?
| Proteins | 2 | 1998 | 342 | 0.040 |
Why?
| Luciferases | 1 | 1998 | 50 | 0.040 |
Why?
| Epidermal Growth Factor | 1 | 1998 | 34 | 0.040 |
Why?
| Glucuronidase | 1 | 1998 | 46 | 0.040 |
Why?
| Repetitive Sequences, Nucleic Acid | 1 | 1998 | 96 | 0.040 |
Why?
| Microscopy, Fluorescence | 1 | 1998 | 162 | 0.040 |
Why?
| Antineoplastic Agents | 2 | 2003 | 1171 | 0.040 |
Why?
| Aortic Aneurysm | 1 | 1998 | 25 | 0.040 |
Why?
| Blood Coagulation | 1 | 1998 | 56 | 0.040 |
Why?
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 1988 | 88 | 0.040 |
Why?
| Lysosomes | 1 | 1998 | 64 | 0.040 |
Why?
| NFATC Transcription Factors | 1 | 2017 | 23 | 0.040 |
Why?
| Jurkat Cells | 1 | 2017 | 29 | 0.040 |
Why?
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 828 | 0.040 |
Why?
| Active Transport, Cell Nucleus | 1 | 2017 | 34 | 0.040 |
Why?
| DNA, Single-Stranded | 1 | 1998 | 87 | 0.040 |
Why?
| Reoperation | 1 | 2000 | 454 | 0.040 |
Why?
| Registries | 1 | 2000 | 522 | 0.040 |
Why?
| Protein Stability | 1 | 2017 | 43 | 0.040 |
Why?
| Transfection | 1 | 1998 | 354 | 0.040 |
Why?
| Arginine | 2 | 1996 | 179 | 0.040 |
Why?
| Binding Sites | 1 | 1998 | 374 | 0.040 |
Why?
| Transcriptional Activation | 1 | 2017 | 121 | 0.040 |
Why?
| Radiopharmaceuticals | 2 | 2010 | 209 | 0.040 |
Why?
| Radiotherapy, Adjuvant | 1 | 1997 | 56 | 0.040 |
Why?
| Gene Deletion | 1 | 1998 | 266 | 0.040 |
Why?
| Permeability | 1 | 1997 | 68 | 0.040 |
Why?
| Base Sequence | 1 | 1998 | 643 | 0.040 |
Why?
| Fluorodeoxyglucose F18 | 2 | 2010 | 192 | 0.040 |
Why?
| Hemodynamics | 3 | 2004 | 228 | 0.040 |
Why?
| Oligopeptides | 1 | 2017 | 89 | 0.040 |
Why?
| Molecular Sequence Data | 1 | 1998 | 792 | 0.030 |
Why?
| Multiple Myeloma | 1 | 2011 | 2929 | 0.030 |
Why?
| Brain | 1 | 2005 | 1328 | 0.030 |
Why?
| Ultrasonography | 2 | 1988 | 436 | 0.030 |
Why?
| Age Factors | 1 | 2000 | 1087 | 0.030 |
Why?
| Parenteral Nutrition, Total | 1 | 1996 | 31 | 0.030 |
Why?
| Cesium Radioisotopes | 1 | 1996 | 4 | 0.030 |
Why?
| Ruthenium Radioisotopes | 1 | 1996 | 2 | 0.030 |
Why?
| Prospective Studies | 3 | 2007 | 2364 | 0.030 |
Why?
| Protein Processing, Post-Translational | 1 | 2017 | 171 | 0.030 |
Why?
| Evans Blue | 1 | 1995 | 2 | 0.030 |
Why?
| Platelet Activating Factor | 1 | 1995 | 2 | 0.030 |
Why?
| Mesenteric Artery, Superior | 1 | 1995 | 10 | 0.030 |
Why?
| Sepsis | 1 | 1998 | 220 | 0.030 |
Why?
| Hospital Mortality | 2 | 2011 | 409 | 0.030 |
Why?
| Hospitalization | 1 | 2000 | 652 | 0.030 |
Why?
| Diagnosis, Differential | 2 | 2011 | 1037 | 0.030 |
Why?
| Gallbladder | 1 | 1995 | 25 | 0.030 |
Why?
| Adenosine Triphosphate | 2 | 1996 | 233 | 0.030 |
Why?
| DNA-Binding Proteins | 1 | 1998 | 427 | 0.030 |
Why?
| Chemotactic Factors | 1 | 1994 | 5 | 0.030 |
Why?
| Complement C5a | 1 | 1994 | 4 | 0.030 |
Why?
| Deferoxamine | 1 | 1994 | 9 | 0.030 |
Why?
| Thiourea | 1 | 1994 | 9 | 0.030 |
Why?
| Muscle, Smooth, Vascular | 1 | 1996 | 130 | 0.030 |
Why?
| Combined Modality Therapy | 1 | 1997 | 637 | 0.030 |
Why?
| Gene Expression | 1 | 2017 | 609 | 0.030 |
Why?
| Cell Differentiation | 2 | 2010 | 651 | 0.030 |
Why?
| Serum Albumin, Radio-Iodinated | 1 | 1994 | 1 | 0.030 |
Why?
| Polymyxin B | 1 | 1994 | 5 | 0.030 |
Why?
| Complement System Proteins | 1 | 1994 | 46 | 0.030 |
Why?
| Therapeutic Irrigation | 1 | 1994 | 30 | 0.030 |
Why?
| Estrogens | 1 | 1996 | 227 | 0.030 |
Why?
| Tomography, X-Ray Computed | 3 | 1988 | 1159 | 0.030 |
Why?
| Drug Tolerance | 1 | 1994 | 60 | 0.030 |
Why?
| Child, Preschool | 3 | 1991 | 3871 | 0.030 |
Why?
| Models, Biological | 1 | 1996 | 727 | 0.030 |
Why?
| Indoles | 1 | 2015 | 278 | 0.030 |
Why?
| Lipid Peroxides | 1 | 1991 | 10 | 0.030 |
Why?
| Infant | 2 | 1991 | 3567 | 0.020 |
Why?
| Enterocolitis, Neutropenic | 1 | 2011 | 6 | 0.020 |
Why?
| Predictive Value of Tests | 2 | 2007 | 903 | 0.020 |
Why?
| Cytokines | 1 | 1994 | 612 | 0.020 |
Why?
| Ileus | 1 | 2011 | 15 | 0.020 |
Why?
| Cell Line, Tumor | 1 | 2015 | 1403 | 0.020 |
Why?
| Postoperative Care | 1 | 1991 | 102 | 0.020 |
Why?
| Patient Transfer | 1 | 2011 | 94 | 0.020 |
Why?
| Gastrointestinal Transit | 1 | 1990 | 4 | 0.020 |
Why?
| Enema | 1 | 1990 | 9 | 0.020 |
Why?
| Barium Sulfate | 1 | 1990 | 12 | 0.020 |
Why?
| Enteral Nutrition | 1 | 1991 | 147 | 0.020 |
Why?
| Hydrogen-Ion Concentration | 2 | 2003 | 175 | 0.020 |
Why?
| Adenomatous Polyposis Coli | 1 | 1990 | 7 | 0.020 |
Why?
| Blotting, Western | 2 | 2005 | 601 | 0.020 |
Why?
| alpha-Fetoproteins | 1 | 2010 | 15 | 0.020 |
Why?
| Intestinal Absorption | 1 | 1990 | 57 | 0.020 |
Why?
| Kaplan-Meier Estimate | 1 | 2011 | 466 | 0.020 |
Why?
| Dogs | 1 | 1990 | 182 | 0.020 |
Why?
| Colitis, Ulcerative | 1 | 1990 | 50 | 0.020 |
Why?
| Diarrhea | 1 | 1990 | 92 | 0.020 |
Why?
| Child | 3 | 1991 | 6847 | 0.020 |
Why?
| Evaluation Studies as Topic | 1 | 1989 | 107 | 0.020 |
Why?
| Patient Discharge | 1 | 2011 | 320 | 0.020 |
Why?
| Adolescent | 2 | 1991 | 6356 | 0.020 |
Why?
| Survival Analysis | 2 | 2003 | 653 | 0.020 |
Why?
| Mice, Inbred C57BL | 2 | 2004 | 1816 | 0.020 |
Why?
| Angiography | 1 | 1988 | 126 | 0.020 |
Why?
| Weight Gain | 1 | 1990 | 240 | 0.020 |
Why?
| Neoplasms | 1 | 1998 | 1235 | 0.020 |
Why?
| Intraoperative Complications | 1 | 1989 | 112 | 0.020 |
Why?
| Aorta, Abdominal | 2 | 1998 | 41 | 0.020 |
Why?
| Pyloric Antrum | 1 | 1986 | 11 | 0.020 |
Why?
| Cytomegalovirus Infections | 1 | 1986 | 34 | 0.020 |
Why?
| Acquired Immunodeficiency Syndrome | 1 | 1986 | 54 | 0.020 |
Why?
| Prostaglandin-Endoperoxide Synthases | 2 | 1996 | 26 | 0.020 |
Why?
| Mastectomy, Extended Radical | 1 | 2005 | 1 | 0.020 |
Why?
| tert-Butylhydroperoxide | 1 | 2005 | 5 | 0.020 |
Why?
| Glucosephosphate Dehydrogenase | 1 | 2005 | 6 | 0.020 |
Why?
| Apolipoprotein A-I | 1 | 2005 | 7 | 0.020 |
Why?
| PC12 Cells | 1 | 2005 | 24 | 0.020 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 102 | 0.020 |
Why?
| Biopsy, Fine-Needle | 1 | 2006 | 103 | 0.020 |
Why?
| Mitosis | 1 | 2005 | 91 | 0.020 |
Why?
| Thioglycolates | 1 | 2005 | 5 | 0.020 |
Why?
| Cell Size | 1 | 2005 | 45 | 0.020 |
Why?
| Cell Count | 1 | 2005 | 147 | 0.020 |
Why?
| Dextran Sulfate | 1 | 2004 | 9 | 0.020 |
Why?
| Platelet Adhesiveness | 1 | 2004 | 13 | 0.020 |
Why?
| Lymphatic Metastasis | 1 | 2005 | 224 | 0.020 |
Why?
| Indicators and Reagents | 1 | 2004 | 36 | 0.020 |
Why?
| Heart Arrest, Induced | 1 | 2004 | 7 | 0.020 |
Why?
| Polyamines | 1 | 2004 | 9 | 0.020 |
Why?
| P-Selectin | 1 | 2004 | 32 | 0.010 |
Why?
| Disease Progression | 1 | 2007 | 825 | 0.010 |
Why?
| Oxidation-Reduction | 1 | 2005 | 322 | 0.010 |
Why?
| Leukocytes | 1 | 2004 | 66 | 0.010 |
Why?
| Extracorporeal Circulation | 1 | 2003 | 9 | 0.010 |
Why?
| Blood Gas Analysis | 1 | 2003 | 30 | 0.010 |
Why?
| Aspartate Aminotransferases | 1 | 2004 | 45 | 0.010 |
Why?
| Probability | 1 | 2004 | 164 | 0.010 |
Why?
| Decanoic Acids | 1 | 2003 | 1 | 0.010 |
Why?
| Alkenes | 1 | 2003 | 3 | 0.010 |
Why?
| Hydroxy Acids | 1 | 2003 | 8 | 0.010 |
Why?
| Mice, Inbred NOD | 1 | 2004 | 96 | 0.010 |
Why?
| ADP Ribose Transferases | 1 | 2003 | 4 | 0.010 |
Why?
| Botulinum Toxins | 1 | 2003 | 5 | 0.010 |
Why?
| Down-Regulation | 1 | 2005 | 348 | 0.010 |
Why?
| Amides | 1 | 2003 | 34 | 0.010 |
Why?
| Mice, Inbred Strains | 1 | 2003 | 161 | 0.010 |
Why?
| Cattle | 1 | 2003 | 210 | 0.010 |
Why?
| Nitric Oxide Synthase Type III | 1 | 2003 | 78 | 0.010 |
Why?
| Autocrine Communication | 1 | 2002 | 8 | 0.010 |
Why?
| Cardiopulmonary Resuscitation | 1 | 2004 | 133 | 0.010 |
Why?
| Radioimmunoassay | 1 | 2002 | 44 | 0.010 |
Why?
| Statistics, Nonparametric | 1 | 2003 | 194 | 0.010 |
Why?
| Kidney Tubules, Proximal | 1 | 2002 | 62 | 0.010 |
Why?
| Reproducibility of Results | 1 | 2006 | 1193 | 0.010 |
Why?
| src-Family Kinases | 1 | 2002 | 51 | 0.010 |
Why?
| Mice, Transgenic | 1 | 2003 | 555 | 0.010 |
Why?
| Mice, Knockout | 1 | 2004 | 841 | 0.010 |
Why?
| Angiotensin II | 1 | 2002 | 157 | 0.010 |
Why?
| Odds Ratio | 1 | 2003 | 545 | 0.010 |
Why?
| Pyrimidines | 1 | 2002 | 192 | 0.010 |
Why?
| Heart | 1 | 2003 | 326 | 0.010 |
Why?
| Cell Line | 1 | 2003 | 1000 | 0.010 |
Why?
| Echocardiography | 1 | 2003 | 378 | 0.010 |
Why?
| Regression Analysis | 1 | 2001 | 395 | 0.010 |
Why?
| Models, Theoretical | 1 | 2001 | 175 | 0.010 |
Why?
| Inflammation | 1 | 2004 | 604 | 0.010 |
Why?
| Hospitals | 1 | 2001 | 175 | 0.010 |
Why?
| Myocardial Infarction | 1 | 2003 | 389 | 0.010 |
Why?
| Case-Control Studies | 1 | 2003 | 1131 | 0.010 |
Why?
| Immunohistochemistry | 1 | 2002 | 973 | 0.010 |
Why?
| Ligation | 1 | 1998 | 59 | 0.010 |
Why?
| Cecum | 1 | 1998 | 63 | 0.010 |
Why?
| Anastomosis, Surgical | 1 | 1998 | 66 | 0.010 |
Why?
| Allopurinol | 1 | 1997 | 7 | 0.010 |
Why?
| Inulin | 1 | 1997 | 7 | 0.010 |
Why?
| Pentoxifylline | 1 | 1997 | 14 | 0.010 |
Why?
| Arterial Occlusive Diseases | 1 | 1998 | 79 | 0.010 |
Why?
| Sodium | 1 | 1997 | 92 | 0.010 |
Why?
| Career Choice | 1 | 1998 | 111 | 0.010 |
Why?
| Femoral Artery | 1 | 1998 | 100 | 0.010 |
Why?
| Family | 1 | 1998 | 170 | 0.010 |
Why?
| Cyclooxygenase 1 | 1 | 1996 | 5 | 0.010 |
Why?
| Constriction | 1 | 1996 | 9 | 0.010 |
Why?
| Immunoenzyme Techniques | 1 | 1996 | 143 | 0.010 |
Why?
| Vascular Surgical Procedures | 1 | 1998 | 165 | 0.010 |
Why?
| Isoenzymes | 1 | 1996 | 168 | 0.010 |
Why?
| Testosterone | 1 | 1996 | 139 | 0.010 |
Why?
| Cholecystitis | 1 | 1995 | 11 | 0.010 |
Why?
| Parenteral Nutrition | 1 | 1995 | 27 | 0.010 |
Why?
| Immunoblotting | 1 | 1995 | 118 | 0.010 |
Why?
| Antibodies | 1 | 1995 | 154 | 0.010 |
Why?
| Homeostasis | 1 | 1996 | 200 | 0.010 |
Why?
| Estradiol | 1 | 1996 | 225 | 0.010 |
Why?
| Membrane Proteins | 1 | 1996 | 341 | 0.010 |
Why?
| Rats, Inbred Strains | 1 | 1992 | 196 | 0.010 |
Why?
| Radiography | 1 | 1989 | 489 | 0.000 |
Why?
| Homosexuality | 1 | 1986 | 4 | 0.000 |
Why?
| Stomach Diseases | 1 | 1986 | 12 | 0.000 |
Why?
| Endoscopy | 1 | 1986 | 124 | 0.000 |
Why?
| Gastrointestinal Diseases | 1 | 1986 | 126 | 0.000 |
Why?
|
|
Turnage's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|